[ Back to EurekAlert! ] Public release date: 24-Sep-2008
[ | E-mail Share Share ]

Contact: Dr. Alan Garber
agarber@bcm.tmc.edu
713-798-0153
Lancet

Liraglutide improves glucose control and increases weight loss in type 2 diabetes patients

LEAD-3 Mono study

Liraglutide, a new treatment for type 2 diabetes, improves blood glucose control compared with a conventional oral treatment glimepiride. Patients given liraglutide injections also recorded increases in weight loss and decreases in blood pressure. These are the conclusions of an Article published early Online and in an upcoming edition of The Lancet, written by Dr Alan Garber, Baylor College of Medicine, Houston, TX, USA, and colleagues.

In this randomised-controlled phase III trial, 746 patients with early type 2 diabetes were assigned to once daily liraglutide 1.2mg, (251 patients) or 1.8mg (247 patients) or glimepiride 8mg (248 patients) for one year. The primary outcome was the change in proportion of glycosylated haemoglobin* (HbA1c). Patients in the three groups had a mean HbA1c of 8.3-8.4% at baseline. The researchers found that HbA1c decreased by 0.51% in the glimepiride group, while in the liraglutide 1.2mg group the reduction was 0.84% and in the liraglutide 1.8mg group it was 1.14%. Proportions of patients achieving HbA1c of both less than 7.0% and less than 6.5% (two internationally accepted targets) were higher for both liraglutide group patients than for glimepiride patients, in both patients who had been receiving treatment before and those who were treatment naive. Five patients in the liraglutide 1.2mg, one in the 1.8mg group and none in the glimepiride group discontinued treatment because of vomiting.

Further, the researchers found that participants in the liraglutide groups lost weight (around 2kg) while those in the glimepiride group gained weight (1kg), when adjusted for the effects of nausea. Systolic blood pressure fell by 0.7 mm Hg in the glimepiride group, compared with 2.1mg Hg in the liraglutide 1.2mg group and 3.6mm Hg in the liraglutide 1.8 mg group. These blood pressure results were only statistically significant for the liraglutide 1.8 mg group versus glimepiride.

The authors conclude: "Treatment with liraglutide as monotherapy provided better glycaemic control for 52-weeks than did glimepiride, a traditional first-line therapy for type 2 diabetes mellitus, in participants previously treated with either diet and exercise or oral antidiabetic monotherapy. Liraglutide improved glycaemic control with a low rate of hypoglycaemia...On the basis of these results, we conclude that liraglutide is safe and effective as initial pharmacological therapy for type 2 diabetes mellitus and has advantages over other drugs used in monotherapy, such as greater reductions in weight, the number of hypoglycaemic events, and systolic blood pressure."

In an accompanying Comment, Dr Sten Madsbad, Hvidovre Hosptial and University of Copenhagen, Denmark, says that treatments such as liraglutide offer new options in the treatment of type 2 diabetes, but adds that their final role "remains to be clarified, after carefully conducted long-term trials with cardiovascular endpoints and safety data."

###

Dr Alan Garber, Baylor College of Medicine, Houston, TX, USA T) +1 713-798-0153 E) agarber@bcm.tmc.edu

Dr Sten Madsbad, Hvidovre Hosptial and University of Copenhagen, Denmark T) +45 2169 1911 E) sten.madsbad@hvh.regionh.dk

Notes to editors: Glycosylated haemoglobin (HbA1c) is a form of haemoglobin used primarily to identify the average plasma glucose concentration over prolonged periods of time. The HbA1c level is proportional to average blood glucose concentration over the previous four weeks to three months. Depending on which international standard is used, the target for type 2 diabetes patients is to reduce their proportion of HbA1c to 7.0% or 6.5%.

Full Article and Comment: http://press.thelancet.com/liraglutide.pdf



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.